Erik Upeslacis
Pfizer (United States)(US)
Publications by Year
Research Areas
CAR-T cell therapy research, Monoclonal and Polyclonal Antibodies Research, Biosimilars and Bioanalytical Methods, Cancer Research and Treatments, Cancer Cells and Metastasis
Most-Cited Works
- → 4-Anilino-6,7-dialkoxyquinoline-3-carbonitrile Inhibitors of Epidermal Growth Factor Receptor Kinase and Their Bioisosteric Relationship to the 4-Anilino-6,7-dialkoxyquinazoline Inhibitors(2000)209 cited
- → Anti-EFNA4 Calicheamicin Conjugates Effectively Target Triple-Negative Breast and Ovarian Tumor-Initiating Cells to Result in Sustained Tumor Regressions(2015)87 cited
- → A Novel GUCY2C-CD3 T-Cell Engaging Bispecific Construct (PF-07062119) for the Treatment of Gastrointestinal Cancers(2020)62 cited
- → The interaction of PKN3 with RhoC promotes malignant growth(2011)49 cited
- → p120 catenin is a key effector of a Ras-PKCɛ oncogenic signaling axis(2013)32 cited
- → Anti-tumor immunity influences cancer cell reliance upon ATG7(2020)24 cited
- → Abstract 818: NG-HER2 ADC (PF-06804103) is superior to trastuzumab emtansine in a mouse 'avatar' head-to-head clinical trial(2018)6 cited
- → Abstract 2113: Caveolae-mediated endocytosis as a novel mechanism of resistance to T-DM1 ADC(2016)5 cited
- → 2-Aryl-4,5,6,7-tetrahydro-1,3-benzothiazol-7-ols as a class of antitumor agents selectively active in securin−/− cells(2010)2 cited
- → Abstract 5425: An anti-Ephrin-A4 calicheamicin conjugate effectively targets triple-negative breast and ovarian tumor-initiating cells to result in sustained tumor regression(2015)2 cited